• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心房颤动合并慢性肾脏病患者的发病情况和治疗。

Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease.

机构信息

Division of Vascular Medicine, Department of Cardiovascular Medicine, University Hospital of Muenster, Muenster, Germany.

Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.

出版信息

Kidney Int. 2015 Jan;87(1):200-9. doi: 10.1038/ki.2014.195. Epub 2014 Jun 4.

DOI:10.1038/ki.2014.195
PMID:24897032
Abstract

Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality but there are few studies available about atrial fibrillation, the most frequent arrhythmia in CKD, and the applied treatment. Based on the prospective German Competence NETwork on Atrial Fibrillation, data of 3138 patients with atrial fibrillation were analyzed and categorized by their estimated glomerular filtration rate (stages 1-3 and 4 plus 5). With advanced CKD, significantly more patients suffered from a more severe form of atrial fibrillation. Despite significantly higher CHADS2 scores in advanced CKD, oral anticoagulation was not prescribed more frequently while antiarrhythmic drugs and catheter ablations were used significantly less often, in contrast to more pacemaker implantations. However, in multivariate hierarchical logistic regression analyses of in-hospital treatments and complications, only hemorrhages and pacemaker implantations turned out to be independently and significantly associated with higher CKD stages. This nationwide study shows that patients with CKD and atrial fibrillation suffer from a markedly higher comorbidity. Thus, while CKD patients have received cardioversions, ablations, antiarrhythmic, or anticoagulation drugs significantly less often in their history, current treatments were not different if adjusted for multiple comorbidities. This might indicate an improvement in the often reported therapeutic nihilism in CKD.

摘要

慢性肾脏病(CKD)与心血管发病率和死亡率增加有关,但关于心房颤动(CKD 中最常见的心律失常)及其应用治疗的研究很少。基于前瞻性德国心房颤动网络,对 3138 例心房颤动患者的数据进行了分析,并根据其估计肾小球滤过率(1-3 期和 4 期加 5 期)进行了分类。随着 CKD 的进展,患有更严重形式的心房颤动的患者明显增多。尽管 CKD 患者的 CHADS2 评分显著升高,但抗凝治疗的处方频率并没有增加,而抗心律失常药物和导管消融的使用频率明显降低,与之相反,起搏器植入的频率却增加了。然而,在住院治疗和并发症的多变量层次逻辑回归分析中,只有出血和起搏器植入与更高的 CKD 分期呈独立且显著相关。这项全国性研究表明,CKD 合并心房颤动的患者合并症明显更高。因此,尽管 CKD 患者在过去的治疗中接受过电复律、消融术、抗心律失常药物或抗凝药物治疗的频率明显较低,但如果考虑到多种合并症,目前的治疗方法并无差异。这可能表明,在 CKD 中经常报道的治疗上的消极态度有所改善。

相似文献

1
Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease.心房颤动合并慢性肾脏病患者的发病情况和治疗。
Kidney Int. 2015 Jan;87(1):200-9. doi: 10.1038/ki.2014.195. Epub 2014 Jun 4.
2
Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation.慢性肾脏病患者接受房颤导管消融术后估算肾小球滤过率的改善
J Cardiovasc Electrophysiol. 2015 Jan;26(1):21-7. doi: 10.1111/jce.12530. Epub 2014 Sep 26.
3
Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease.他汀类药物治疗的延续与慢性肾脏病患者和非慢性肾脏病患者心房颤动/扑动风险降低的关系。
Atherosclerosis. 2014 Jan;232(1):224-30. doi: 10.1016/j.atherosclerosis.2013.11.036. Epub 2013 Nov 19.
4
Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients.慢性肾脏病作为高血压患者新发心房颤动的独立危险因素。
J Hypertens. 2010 Aug;28(8):1738-44. doi: 10.1097/HJH.0b013e32833a7dfe.
5
Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?慢性肾脏病是否提高 CHADS2 和 CHA2DS2-VASc 卒中分层风险评分预测房颤的价值?
Thromb Haemost. 2013 May;109(5):956-60. doi: 10.1160/TH13-01-0054. Epub 2013 Mar 21.
6
[Oral anticoagulation in chronic kidney disease with atrial fibrillation].[慢性肾脏病合并心房颤动的口服抗凝治疗]
Med Clin (Barc). 2015 May 21;144(10):452-6. doi: 10.1016/j.medcli.2014.03.029. Epub 2014 Jun 2.
7
Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial.房颤伴慢性肾病患者的心率控制与节律控制及结局:来自 GUSTO-III 试验的数据。
Cardiol J. 2013;20(4):439-46. doi: 10.5603/CJ.2013.0104.
8
Stroke prevention in atrial fibrillation patients with chronic kidney disease.房颤合并慢性肾脏病患者的卒中预防。
Can J Cardiol. 2013 Jul;29(7 Suppl):S71-8. doi: 10.1016/j.cjca.2013.04.005.
9
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study.老年住院患者心房微栓塞的受害者:大脑和肾脏?REPOSI 研究的数据。
Eur J Intern Med. 2015 May;26(4):243-9. doi: 10.1016/j.ejim.2015.02.018. Epub 2015 Mar 5.
10
Is there association between changes in eGFR value and the risk of permanent type of atrial fibrillation? Analysis of valvular and non-valvular atrial fibrillation population.估算肾小球滤过率(eGFR)值的变化与永久性房颤风险之间是否存在关联?瓣膜性和非瓣膜性房颤人群分析。
Kidney Blood Press Res. 2014;39(6):600-8. doi: 10.1159/000368473. Epub 2014 Dec 15.

引用本文的文献

1
Comparison between non-vitamin K oral antagonist versus warfarin in atrial fibrillation with and without valvular heart disease: a systematic review and meta-analysis.非维生素K口服抗凝剂与华法林在伴或不伴有心脏瓣膜病的心房颤动患者中的比较:一项系统评价和荟萃分析。
Egypt Heart J. 2024 Aug 9;76(1):102. doi: 10.1186/s43044-024-00535-w.
2
Atrial Fibrillation and Chronic Kidney Disease: Aetiology and Management.心房颤动与慢性肾脏病:病因与管理
Rev Cardiovasc Med. 2024 Apr 9;25(4):143. doi: 10.31083/j.rcm2504143. eCollection 2024 Apr.
3
The incidence and impact of atrial fibrillation on hospitalized Coronavirus disease-2019 patients.
因 COVID-19 住院患者中房颤的发生率及其影响。
Clin Cardiol. 2024 Feb;47(2):e24240. doi: 10.1002/clc.24240.
4
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada.利伐沙班与华法林在不同肾小球滤过率水平的心房颤动患者中的安全性和有效性:一项基于澳大利亚和加拿大人群的研究。
Kidney Med. 2023 May 16;5(7):100675. doi: 10.1016/j.xkme.2023.100675. eCollection 2023 Jul.
5
Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting.在意大利临床环境中对拟钙剂治疗慢性肾脏病继发性甲状旁腺功能亢进的真实世界评估。
Healthcare (Basel). 2022 Apr 11;10(4):709. doi: 10.3390/healthcare10040709.
6
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.根据肾功能分层的心房颤动患者中,多非利特与安慰剂的疗效和安全性:EURIDIS-ADONIS 试验的事后分析。
Clin Cardiol. 2022 Jan;45(1):101-109. doi: 10.1002/clc.23765. Epub 2022 Jan 12.
7
Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD.成人新发房颤伴或不伴 CKD 的管理。
J Am Soc Nephrol. 2022 Feb;33(2):442-453. doi: 10.1681/ASN.2021060744. Epub 2021 Dec 17.
8
Chronic kidney disease and risks of adverse clinical events in patients with atrial fibrillation.慢性肾脏病与心房颤动患者不良临床事件的风险
J Geriatr Cardiol. 2021 Nov 28;18(11):867-876. doi: 10.11909/j.issn.1671-5411.2021.11.002.
9
Impact of kidney function on the occurrence of new-onset atrial fibrillation in patients with ST-elevation myocardial infarction.肾功能对 ST 段抬高型心肌梗死患者新发心房颤动的影响。
Anatol J Cardiol. 2021 Sep;25(9):638-645. doi: 10.5152/AnatolJCardiol.2021.35332.
10
Efficacy and Safety of Non-Vitamin K Anticoagulants for Atrial Fibrillation in Relation to Different Renal Function Levels: A Network Meta-Analysis.非维生素 K 拮抗剂在不同肾功能水平下对房颤的疗效和安全性:网络荟萃分析。
Cardiovasc Ther. 2020 Apr 22;2020:2683740. doi: 10.1155/2020/2683740. eCollection 2020.